EGFR and cancer: Mutations or deletions in EGFR also result in ligand‐independent receptor activation in certain cancers.[55, 56, 57] Especially drug‐resistant EGFR mutations also facilitate the formation of ligand‐independent, kinase‐active oligomers, which in turn promote and stabilize the assembly of oligomer‐dependent active dimer subunits, thereby bypassing the requirement for ligand binding.